Hims & Hers Health Inc (NYSE:HIMS) stock traded higher on Thursday after an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list.
The Nasdaq is down 1.96% while the S&P 500 has shed 1.32%, and HIMS is also outperforming a Healthcare sector that’s up 0.87%.
Advisory Vote Drives Sentiment
The price movement follows a decision by the Pharmacy Compounding Advisory Committee (PCAC) during its scheduled July 23–24 meetings regarding bulk lists under the 503A framework.
Under this regulatory framework, inclusion on the 503A Bulk List allows state-licensed pharmacies to compound reviewed peptides.
Earlier in July, BofA Securities analyst Allen Lutz noted that preliminary FDA briefing materials had recommended against adding seven peptides to the list, citing concerns over limited clinical evidence, unresolved safety and quality questions and insufficient support for proposed use cases.
However, Lutz noted that the FDA’s preliminary position required advisory panel input before any final determination.
Short Interest Declines
Short interest in Hims & Hers Health decreased during the latest reporting period, falling from 65.47 million to 61.17 million. This drop leaves 31.82% of the company’s publicly available stock short.
Based on a recent average daily volume of 18.92 million shares, it would take 3.23 days for holders of this short interest to close out their positions without sending the stock sharply higher.
Upcoming Earnings Expectations
Hims & Hers Health will report second quarter earnings on August 10. Consensus estimates project earnings per share of -$0.04 alongside quarterly revenue of $724.14 million.
Recent analyst actions include BofA Securities maintaining a Neutral rating while raising its price forecast to $37 on July 9, and Canaccord Genuity maintaining a Buy rating while raising its forecast to $40 on July 1.
Technical Analysis
HIMS is now trading 0.6% above its 20-day SMA ($34.74) and 15.4% above its 50-day SMA ($30.28), which keeps the intermediate trend pointed up after the recent swing low in May. It’s also 12% above the 200-day SMA ($31.20), a constructive sign for trend followers watching whether the stock can hold above longer-term trend gauges.
Momentum looks more reset than stretched, with RSI at 54.63, which signals neutral conditions rather than an overbought chase. The moving-average structure is mixed: the 20-day SMA is above the 50-day SMA (bullish), but the 50-day SMA remains below the 200-day SMA, reflecting the lingering "death cross" that formed in December.
- Key Resistance: $36
- Key Support: $30
HIMS Price Action: Hims & Hers Health shares were up 5.68% at $33.47 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Lori Butcher / Shutterstock
Login to comment